STRATA Skin Sciences Gains Japanese Approval of XTRAC Momentum 1.0 Device

Japan’s Ministry of Health, Labor, and Welfare has approved STRATA Skin Sciences Inc.’s XTRAC Momentum 1.0 device.

The company initially launched XTRAC Momentum in the United States in early 2022. The device’s immediate commercial rollout will ensue through JMEC Co. Ltd., STRATA’s longstanding Japanese strategic partner and distributor. STRATA’s excimer devices are currently used by more than 300 hospitals and private practice dermatology clinics in Japan.
 
“With this regulatory approval, we are now able to offer the Momentum device—our most advanced excimer laser—into the Japanese dermatology market. Working with JMEC, we look forward to introducing doctors and patients to the benefits of Momentum for the treatment of various dermatology conditions, such as psoriasis, eczema, and vitiligo,” STRATA President/CEO Dr. Dolev Rafaeli said.
 
The company’s XTRAC excimer laser technology precisely delivers targeted UVB light therapy to specific treatment areas of the skin, for both adult and pediatric patients suffering from inflammatory skin conditions such as psoriasis, atopic dermatitis, and vitiligo. The new XTRAC Momentum 1.0 represents the latest in excimer laser technology and delivers higher power and a faster repetition rate than the current models. The Momentum also offers a new user interface and slim design, both intended to improve the treatment experience.
 
STRATA Skin Sciences develops, commercializes, and markets products for the in-office treatment of various dermatologic conditions. Its products include the XTRAC excimer laser, VTRAC lamp systems, and the TheraClearX Acne Therapy System. STRATA Skin Sciences is based in Horsham, Pa.